INCB059872 + pembrolizumab + epacadostat

INCB059872 + pembrolizumab + epacadostat is a **triple combination regimen** of three investigational and/or approved agents: - **INCB059872** is an oral, small molecule, irreversible inhibitor of lysine-specific demethylase 1A (LSD1/KDM1A), developed by Imago BioSciences/Incyte, with epigenetic and differentiation-inducing anti-tumor properties. - **Pembrolizumab** (Keytruda, developed by Merck) is a humanized monoclonal antibody targeting programmed death-1 (PD-1), functioning as an immune checkpoint inhibitor to promote anti-tumor T cell activity. - **Epacadostat** is a small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme involved in tryptophan metabolism whose inhibition is hypothesized to enhance anti-tumor immune responses. This combination is tested as an investigational regimen for the treatment of advanced or metastatic solid tumors, such as melanoma and urothelial carcinoma, designed to simultaneously target tumor cell epigenetics (LSD1 inhibition) and overcome tumor immune suppression (PD-1 and IDO1 inhibition).